TY - JOUR T1 - One-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00103-2021 SP - 00103-2021 AU - Anil J. Trindade AU - Tany Thaniyavarn AU - Nikroo Hashemi AU - Antonio Coppolino AU - John C. Kennedy AU - Hari R. Mallidi AU - Souheil El-Chemaly AU - Hilary J. Goldberg Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/05/13/23120541.00103-2021.abstract N2 - Advanced hepatic fibrosis and cirrhosis are absolute contraindications to lung transplantation. [1] However, whether fatty liver disease with mild-moderate fibrosis contributes to increased adverse outcomes post-lung transplantation remains unknown.We present a retrospective analysis of patients transplanted at Brigham and Women's Hospital between 2015–2017 to identify whether patients with mild-moderate non-alcoholic fatty liver disease (NAFLD) experience increased short-term complications compared to patients with normal liver architecture. Patients with advanced (F3–F4) fibrosis and/or cirrhosis were considered non-suitable transplant candidates, a priori. This study was powered for a difference in index hospital-free days within the first 30 days of 25% (alpha=0.05, beta=0.8). Secondary outcomes included index intensive care unit (ICU) free days within the first 10 days post-transplant, perioperative blood product transfusion, incidence of index hospitalisation arrhythmias and delirium, need for insulin on discharge post-transplant, tacrolimus dose required to maintain a trough of 8–12 ng·mL−1 at index hospital discharge, and 1-year post-transplant incidence of insulin-dependent diabetes, acute kidney injury, acute cellular rejection, unplanned hospital readmissions, and infection.One hundred fifty patients underwent lung transplantation between 2015–2017 and were included in the analysis; of these patients 40 (27%) had evidence of NAFLD. Median index hospital-free days for patients with NAFLD were non-inferior to those without (16 days, IQR 10.5–19.5 versus 12 days, IQR 0–18.0, p= 0.03). Regarding secondary outcomes, both index hospitalisation and 1-year outcomes were non-inferior between patients with NAFLD and those with normal liver architecture.This study demonstrates that mild-moderate severity NAFLD may not be a contraindication to lung transplantation.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Trindade has nothing to disclose.Conflict of interest: Dr. Thaniyavarn has nothing to disclose.Conflict of interest: Dr. Hashemi has nothing to disclose.Conflict of interest: Dr. Coppolino has nothing to disclose.Conflict of interest: Dr. Kennedy has nothing to disclose.Conflict of interest: Dr. Mallidi has nothing to disclose.Conflict of interest: Dr. El-Chemaly has nothing to disclose.Conflict of interest: Dr. Goldberg has nothing to disclose. ER -